These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

221 related items for PubMed ID: 37436697

  • 1. Cost-effectiveness analysis of 7 treatments in metastatic hormone-sensitive prostate cancer: a public-payer perspective.
    Yoo M, Nelson RE, Haaland B, Dougherty M, Cutshall ZA, Kohli R, Beckstead R, Kohli M.
    J Natl Cancer Inst; 2023 Nov 08; 115(11):1374-1382. PubMed ID: 37436697
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness model of abiraterone plus prednisone, cabazitaxel plus prednisone and enzalutamide for visceral metastatic castration resistant prostate cancer therapy after docetaxel therapy resistance.
    Barqawi YK, Borrego ME, Roberts MH, Abraham I.
    J Med Econ; 2019 Nov 08; 22(11):1202-1209. PubMed ID: 31452414
    [Abstract] [Full Text] [Related]

  • 4. Cost-Utility Analysis of Darolutamide Combined with Androgen Deprivation Therapy for Patients with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer in China.
    Ming J, Wu Y, Han R, Xu X, Waldeck R, Hu S.
    Adv Ther; 2023 Mar 08; 40(3):1087-1103. PubMed ID: 36630046
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness of enzalutamide versus apalutamide versus androgen deprivation therapy alone for the treatment of metastatic castration-sensitive prostate cancer in Canada.
    Saad F, Chilelli A, Hui B, Muratov S, Ganguli A, North S, Shayegan B.
    J Med Econ; 2022 Mar 08; 25(1):583-590. PubMed ID: 35469527
    [Abstract] [Full Text] [Related]

  • 7. Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer.
    Sathianathen NJ, Oestreich MC, Brown SJ, Gupta S, Konety BR, Dahm P, Kunath F.
    Cochrane Database Syst Rev; 2020 Dec 12; 12(12):CD013245. PubMed ID: 33314020
    [Abstract] [Full Text] [Related]

  • 8. Survival modelling and cost-effectiveness analysis of treatments for newly diagnosed metastatic hormone-sensitive prostate cancer.
    Barbier MC, Tomonaga Y, Menges D, Yebyo HG, Haile SR, Puhan MA, Schwenkglenks M.
    PLoS One; 2022 Dec 12; 17(11):e0277282. PubMed ID: 36327294
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness analysis of Abiraterone Acetate versus Docetaxel in the management of metastatic castration-sensitive prostate cancer: Hong Kong's perspective.
    Chiang CL, So TH, Lam TC, Choi HCW.
    Prostate Cancer Prostatic Dis; 2020 Mar 12; 23(1):108-115. PubMed ID: 31273290
    [Abstract] [Full Text] [Related]

  • 11. Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol.
    Attard G, Murphy L, Clarke NW, Sachdeva A, Jones C, Hoyle A, Cross W, Jones RJ, Parker CC, Gillessen S, Cook A, Brawley C, Gilson C, Rush H, Abdel-Aty H, Amos CL, Murphy C, Chowdhury S, Malik Z, Russell JM, Parkar N, Pugh C, Diaz-Montana C, Pezaro C, Grant W, Saxby H, Pedley I, O'Sullivan JM, Birtle A, Gale J, Srihari N, Thomas C, Tanguay J, Wagstaff J, Das P, Gray E, Alzouebi M, Parikh O, Robinson A, Montazeri AH, Wylie J, Zarkar A, Cathomas R, Brown MD, Jain Y, Dearnaley DP, Mason MD, Gilbert D, Langley RE, Millman R, Matheson D, Sydes MR, Brown LC, Parmar MKB, James ND, STAMPEDE investigators.
    Lancet Oncol; 2023 May 12; 24(5):443-456. PubMed ID: 37142371
    [Abstract] [Full Text] [Related]

  • 12. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.
    Fizazi K, Foulon S, Carles J, Roubaud G, McDermott R, Fléchon A, Tombal B, Supiot S, Berthold D, Ronchin P, Kacso G, Gravis G, Calabro F, Berdah JF, Hasbini A, Silva M, Thiery-Vuillemin A, Latorzeff I, Mourey L, Laguerre B, Abadie-Lacourtoisie S, Martin E, El Kouri C, Escande A, Rosello A, Magne N, Schlurmann F, Priou F, Chand-Fouche ME, Freixa SV, Jamaluddin M, Rieger I, Bossi A, PEACE-1 investigators.
    Lancet; 2022 Apr 30; 399(10336):1695-1707. PubMed ID: 35405085
    [Abstract] [Full Text] [Related]

  • 13. Comparison of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis.
    Wang L, Paller CJ, Hong H, De Felice A, Alexander GC, Brawley O.
    JAMA Oncol; 2021 Mar 01; 7(3):412-420. PubMed ID: 33443584
    [Abstract] [Full Text] [Related]

  • 14. A Cost-Effectiveness Analysis of Systemic Therapy for Metastatic Hormone-Sensitive Prostate Cancer.
    Sung WWY, Choi HCW, Luk PHY, So TH.
    Front Oncol; 2021 Mar 01; 11():627083. PubMed ID: 33718198
    [Abstract] [Full Text] [Related]

  • 15. Treatments for Metastatic Hormone-sensitive Prostate Cancer: Systematic Review, Network Meta-analysis, and Benefit-harm assessment.
    Menges D, Yebyo HG, Sivec-Muniz S, Haile SR, Barbier MC, Tomonaga Y, Schwenkglenks M, Puhan MA.
    Eur Urol Oncol; 2022 Dec 01; 5(6):605-616. PubMed ID: 35599144
    [Abstract] [Full Text] [Related]

  • 16. Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study.
    Saad F, Efstathiou E, Attard G, Flaig TW, Franke F, Goodman OB, Oudard S, Steuber T, Suzuki H, Wu D, Yeruva K, De Porre P, Brookman-May S, Li S, Li J, Thomas S, Bevans KB, Mundle SD, McCarthy SA, Rathkopf DE, ACIS Investigators.
    Lancet Oncol; 2021 Nov 01; 22(11):1541-1559. PubMed ID: 34600602
    [Abstract] [Full Text] [Related]

  • 17. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.
    Chi KN, Protheroe A, Rodríguez-Antolín A, Facchini G, Suttman H, Matsubara N, Ye Z, Keam B, Damião R, Li T, McQuarrie K, Jia B, De Porre P, Martin J, Todd MB, Fizazi K.
    Lancet Oncol; 2018 Feb 01; 19(2):194-206. PubMed ID: 29326030
    [Abstract] [Full Text] [Related]

  • 18. Abiraterone acetate to treat metastatic castration-resistant prostate cancer in combination with prednisone.
    Duarte C, Jimeno A, Kessler ER.
    Drugs Today (Barc); 2019 Jan 01; 55(1):5-15. PubMed ID: 30740608
    [Abstract] [Full Text] [Related]

  • 19. Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study.
    Yu EY, Kolinsky MP, Berry WR, Retz M, Mourey L, Piulats JM, Appleman LJ, Romano E, Gravis G, Gurney H, Bögemann M, Emmenegger U, Joshua AM, Linch M, Sridhar S, Conter HJ, Laguerre B, Massard C, Li XT, Schloss C, Poehlein CH, de Bono JS.
    Eur Urol; 2022 Jul 01; 82(1):22-30. PubMed ID: 35397952
    [Abstract] [Full Text] [Related]

  • 20. Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
    Smith MR, Saad F, Rathkopf DE, Mulders PFA, de Bono JS, Small EJ, Shore ND, Fizazi K, Kheoh T, Li J, De Porre P, Todd MB, Yu MK, Ryan CJ.
    Eur Urol; 2017 Jul 01; 72(1):10-13. PubMed ID: 28314611
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.